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Edited by Michael R. BubbAbstract The eﬀect of a synthetic cyclic disulﬁde compound,
SA3443, on neovascularization was investigated. In vitro, en-
zyme-linked immunosorbent assay and RT-PCR demonstrated
that SA3443 suppressed the expression of the hypoxia-induced
vascular endothelial growth factor (VEGF) at both protein and
mRNA levels in ARPE-19 cells. In vivo, the administration of
SA3443 to mice with laser-induced choroidal neovascularization
(CNV) suppressed the leakage from the lesions and reduced their
size. Furthermore, the expression level of VEGF protein was sig-
niﬁcantly reduced by the administration of SA3443. Taken to-
gether, our results demonstrate that SA3443 suppresses VEGF
production and reduces vascular leakage and the growth of
mouse experimental CNV.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Exudative age-related macular degeneration (AMD), due to
choroidal neovascularization (CNV), is one of the leading
causes of severe visual loss in developed countries [1]. Avail-
able evidence suggests that the vascular endothelial growth
factor (VEGF) plays a pivotal role in the development of
CNV [2–4], and several compounds with properties to inhibit
VEGF production [5] or VEGF signaling pathways suppress
CNV in experimental CNV models and in human CNV [6].
In addition, several drugs are under intensive study for possi-
ble clinical application [4–7]. Therefore, as a ﬁrst step to iden-
tify compounds that inhibit the development of CNV, it is
reasonable to screen compounds with VEGF-antagonizing
properties.
The cyclic disulﬁde compound, SA3443 [(4R)-hexahydro-
7,7-dimethyl-6-oxo-1, 2,5-dithiazocine-4-carboxylic acid], syn-
thesized by oxidative cyclization of the dithiol derivatives,
possesses various pharmacological activities [8–19]. In vivo,
SA3443 protects liver damage in acute hepatic injuries induced
chemically [9] or immunologically [11], and chronic liver inju-*Corresponding author. Fax: +81 3 3817 0798.
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[8]. Moreover, it has inhibited alpha naphthyl isothiocya-
nate-induced intrahepatic cholestasis in rats [18]. Additionally,
it has inhibited glucocorticoid-induced cataract formation in
developing chick embryos [15]. Several lines of evidence
suggest that these eﬀects are mediated, at least in part, by
its anti-inﬂammatory properties [11,13,14]. For example,
in vitro, SA3443 inhibits the production of tumor necrosis fac-
tor (TNF)-like factor from liver macrophages [14]. In vivo,
SA3443 augments natural killer activity and cytotoxic T lym-
phocyte activity [13]. Additionally, SA3443 suppress antibody
response through the inhibition of macrophage antigen-pre-
senting cell activity [12]. It also inhibits lymphocyte activating
factor pathway in vitro [11].
Several types of disulﬁde compound related to SA3443 pos-
sess anti-VEGF properties [20,21]. For example, a disulﬁde
compound, bucillamine, which was recently demonstrated to
eﬀectively suppress CNV in rats [5], is shown to possess anti-
VEGF properties [20,21]. These ﬁndings led us to examine
the eﬀect of SA3443 on hypoxia-induced VEGF protein
in vitro. Furthermore, we investigated the eﬀects of SA3443
on the activity of a laser-induced CNV model in mice and
VEGF protein level upregulated in lasered eyes in vivo.2. Materials and methods
2.1. Cell culture
A human retinal pigment epithelial cell line, ARPE-19, was pur-
chased from American Type Culture Collection (ATCC; Manassas,
VA, USA). Cell cultures were maintained in DMEM/F12 (Gibco
BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine
serum (FBS; Gibco BRL), penicillin (100 U/ml) and streptomycin
(100 lg/ml) (Gibco BRL).
2.2. Eﬀects of SA3443 on hypoxia-induced VEGF by APRE-19 cells
To investigate the eﬀects of SA3443 on hypoxia-induced VEGF pro-
duction, ARPE-19 cells (passage 33) were seeded in 48-well plates
(5 · 104 cells/well) under 5% CO2/95% air. After incubation at 37 C
for 24 h, the culture medium was replaced with serum-free DMEM/
F-12 to arrest the cell growth. After 24 h, the medium was replaced
with DMEM/F-12 containing 1%FBS. Immediately thereafter, indi-
cated concentrations of SA3443 diluted in methylcellulose, provided
from Santen Pharmaceutical Co. (Osaka, Japan), or methylcellulose
alone was added to the medium. One hour after the addition of the
compound, the cells were exposed to hypoxia (1%O2/5%CO2/94%N2)
using a multigas incubator (Jyuuji Field, Tokyo, Japan) or were incu-
bated under 5%CO2/95% air. For an enzyme-linked immunosorbent
assay (ELISA), the medium was collected after 24 h, centrifuged atblished by Elsevier B.V. All rights reserved.
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the concentration of VEGF was analyzed. Results are expressed as
means ± S.E. of eight wells. For semi-quantative reverse transcriptase
polymerase chain reaction (RT-PCR), the cells were lysed with a lysis
buﬀer after 24 h and the total RNA, isolated by RNeasy (RNeasy Li-
pid Tissue Mini Kit; Qiagen), was subjected to RT-PCR analysis.
2.3. Animals
C57bl/6 mice weighing between 20 and 25 g were obtained from
CLEA Japan (Tokyo, Japan). All experiments were conducted in
accordance with the Animal Care and Use Committee and the Associ-
ation for Research in Vision and Ophthalmology Statement for the
Use of Animals in Ophthalmic and Vision Research.
2.4. Experimental CNV
Experimental CNV was created as described elsewhere with minor
modiﬁcations [5,22,23]. Brieﬂy, a general anesthesia was induced with
an intraperitoneal injection (1 ml/kg) of a mixture (1:1) of ketamine
hydrochloride (Ketalar, Sankyo, Tokyo, Japan) and xylazine hydro-
chloride (Celactal, Bayer, Tokyo, Japan). The pupils were dilated
with one drop of 0.5% tropicamide (Mydrin M, Santen Pharmaceu-
tical, Osaka, Japan) for photocoagulation. Six laser photocoagulations
were applied to each eye between the major retinal vessels around the
optic disc with a diode-laser photocoagulator (DC-3000, NIDEK,
Osaka, Japan) and a slit lamp delivery system (SL150, Topcon, Tokyo,
Japan) at a spot size of 75 lm, duration of 0.05-s, and intensity of
220 mW.
The C57bl/6 mice subjected to laser photocoagulation were orally
administered 100 mg/kg (low-dose group) or 300 mg/kg (high-dose
group) of SA3443 in 1% methylcellulose or 1% methylcellulose alone
(control group). Each drug was administered just after the photocoag-
ulation (on day 0) and given once daily thereafter. The concentrations
were selected on the basis of previous studies [8–19].
2.5. Grading of CNV with ﬂuorescein angiography
A total of 169 animals were used to investigate the eﬀects of SA3443
on leakage from CNV lesions (where on day 3, n = 41, 34 and 18 ani-
mals and on day 7, n = 51, 15 and 10 animals for the control, low-dose
and high-dose groups, respectively). The lesions were studied on days 3
and 7 using ﬂuorescein angiography (FA) as described elsewhere [5,22]
with the observer masked as to treatment. The intensity of staining in
late-phase FA (100–150 s after ﬂuorescein injection) was scored in a
masked manner as follows: Score 0, no staining; score 1, slight leakage;
score 2, moderate leakage; score 3, strong leakage.
2.6. Measurement of the CNV size by choroidal ﬂatmounts
A total of 36 mice were used for choroidal ﬂatmount analysis (n = 4
and 8 mice in each of the three groups on day 3 and day 7, respec-
tively). Three and seven days after laser treatment, the size of the
CNV lesions was measured in choroidal ﬂatmounts, as previously de-
scribed [24]. After the mice had been anesthetized and perfused with
1 ml phosphate-buﬀered saline (PBS) containing 50 mg/ml FITC-con-
jugated dextran (4.4 kDa, 50 mg/kg BW; Sigma), the eyes were enucle-
ated, and then, the cornea and lens were removed, and the entire retina
carefully dissected from the eyecup. Radial cuts were made from the
edge to the equator, and the eyecup was ﬂatmounted on the slide glass
with the sclera facing down. Flatmounts were examined by ﬂuores-
cence microscopy (Olympus DP50) and the images were taken using
a CCD camera. The data were uploaded (using Studio lite), and the
area of CNV was outlined and measured using the public domain
NIH image program. For statistical analysis, the lesion sizes of the
two eyes were averaged to give one value for each animal. Data are
presented by means ± S.E.2.7. VEGF protein levels in the posterior eye segments
A total of 42 mice were used to explore the VEGF protein levels in the
posterior eye segments (n = 6 in each group). After mice were sacriﬁced
by cervical dislocation, the eyes were immediately enucleated. The ret-
ina, choroid and sclera were carefully isolated and placed into 150 ll of
RIPA buﬀer (20 mM Tris–HCl, pH 7.4, SDS 0.1%, Triton X-100 1%,
and sodium deoxycholate 1%) supplemented with a protease inhibitor
cocktail (Boehringer–Mannheim, Indianapolis, IN) and sonicated.
Then, the lysate was centrifuged at 14000 rpm for 15 min at 4 C and
the VEGF levels in the supernatant were determined with an ELISA.2.8. Real time RT-PCR
Total RNA, extracted from the cells as described above, was treated
with 10 units of RNase-free DNase I (TOYOBO, Osaka, Japan) in the
presence of 10 units of placental ribonuclease inhibitor (TOYOBO) to
eliminate possible DNA contamination. Two lg of mRNA was then
converted to cDNA in a 20 ll reaction mixture using Superscript II re-
verse transcriptase (Gibco BRL, Rockville, MD, USA) as recom-
mended by the manufacturer. One ll of each RT reaction was then
added to a standard 20 ll PCR mixture. PCR was performed on a
thermocycler (Light Cycler; Roche Diagnostics, Burgdorf, Switzer-
land) with nuclear stain (SYBR Green; Applied Biosystems, Inc., Fos-
ter City, CA) reagents according to the manufacturers instructions.
The ampliﬁcation of the PCR products was quantiﬁed by the measure-
ment of ﬂuorescence associated with the binding of the double-
stranded DNA to the SYBR green dye in the reaction mixture. The
primers used in this study were: human VEGF forward primer, 5 0-
CAGCGCAGCTACTGCCATCCAATCGAGA-30, and reverse pri-
mer, 5 0-GCTTGTCACATCTGCAAGTACGTTCGTTTA-30. After
1 min preincubation at 95 C, ampliﬁcation was performed for 45 cy-
cles consisting of 10 s of denaturing at 95 C, 10 s of annealing at
55 C , and 10 s of extension at 72 C.
2.9. Enzyme-linked immunosorbent assay for VEGF
The concentration of VEGF in the cell culture medium and in the
ocular tissue samples was measured using an ELISA assay kit (R&D
systems, Minneapolis, MN, USA) according to the manufacturers
protocol. Absorbance at 450 nm was measured using a microplate
reader (Model 3550, Bio Rad). In the ocular tissue samples, the VEGF
protein levels were normalized by the total protein content, as deter-
mined by a BCA kit (Bio Rad).
2.10. Statistical analysis
VEGF protein levels in the cell culture medium were evaluated by
Students or Apsin–Welchs t-test or one-way analysis of variance (AN-
OVA) followed byDunnetts post hoc test. The ﬂuorescein angiography
score was evaluated by a Mann–Whitney U test with Bonferronis cor-
rection. The size of the CNV lesions was evaluated by ANOVA fol-
lowed by Dunnetts post hoc test. Values of P < 0.05 were considered
statistically signiﬁcant for all forms of statistical analysis used.3. Results
3.1. Eﬀects of SA3443 on hypoxia induced VEGF production
in ARPE-19 cells
To examine the eﬀect of SA3443 on VEGF after ARPE-19
cells were exposed to hypoxia, ELISA analysis and real-time
PCRwere performed. ELISA analysis revealed that VEGF pro-
tein was upregulated under hypoxic conditions. Upregulated
expression of VEGF decreased in the presence of SA3443 in a
concentration-dependent manner (Fig. 1A). Real-time PCR
also disclosed that SA3443 treatment reduced the expression
of VEGF at mRNA level (Fig. 1B).
3.2. Eﬀects of SA3443 on CNV leakage
The leakage from the CNV lesions was examined with FA
on days 3 and 7. Mice treated with SA3443 at a high dose
(300 mg/kg) showed a signiﬁcant decrease in leakage as judged
by the FA score (Fig. 2), suggesting that the oral administra-
tion of SA3443 at a high dose eﬀectively suppressed the leak-
age from CNV lesions.3.3. Eﬀects of SA3443 on CNV lesion size
To examine whether SA3443 treatment inhibits CNV
growth, the area of CNV was analyzed by choroidal ﬂat-
mounts. The CNV lesion size on day 3 was no diﬀerent in
the control, low-dose and high-dose groups (Fig. 3A and C).
However, on day 7, the size of the CNV lesions in the low-
Fig. 1. SA3443 suppresses the expression of hypoxia-induced VEGF
in ARPE-19 cells. (A) SA3443 was added at a concentration of 1 ·
101–5 · 102 mM. VEGF protein levels in the culture medium of
ARPE-19 cells measured with an ELISA. (B) Real-time RT-PCR
analysis of VEGF transcripts. SA3443 was added at a concentration of
1 · 102 mM. Graphs show the average; error bars indicate S.D. n = 8
(A) and n = 5 (B) in each group. +: P < 0.05 vs. normoxia control; \:
Bonferroni corrected P < 0.05 vs. non-treated hypoxia control.
Fig. 2. Decreased FA leakage in SA3443-treated mice. Eﬀects of
SA3443 on vascular leakage from the laser-induced CNV lesions as
assessed by ﬂuorescein angiography on days 3 and 7 from low-dose
(100 mg/kg) and high-dose (300 mg/kg) groups. Bars show the mean
intensity score of ﬂuorescein leakage; error bars indicate S.D.
Frequency distribution for the FA scores in each group is shown in
the table to the right of the graph. \\: Bonferroni corrected P < 0.05 vs.
non-treated control.
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that in the control (Fig. 3B and C).
3.4. Eﬀects of SA3443 on the expression levels of VEGF in the
laser-treated eyes
To conﬁrm whether the reduction of the CNV size and leak-
age were accompanied by the downregulated expression of
VEGF, concentrations of VEGF were examined in the ocular
tissues. On day 3, the VEGF protein was upregulated in the
lasered eyes compared to that in the non-treated eyes
(Fig. 4). The VEGF protein levels were less in the SA3443-trea-
ted groups than those in the control group (Fig. 4; columns 2–4). By day 7, VEGF protein levels in the control group had fur-
ther increased (Fig. 4; columns 2 and 5). The VEGF protein
levels in the SA3433-treated groups were also less than those
in the control group (Fig. 4; columns 5–7).4. Discussion
Previous studies have demonstrated that VEGF is an angio-
genic factor [25,26] that is upregulated in and localized to the
CNV lesion [2,27], suggesting that VEGF plays an important
role in CNV formation [4]. Actually, several compounds with
anti-VEGF properties eﬀectively suppress CNV [28]. The
in vitro data of the present study demonstrate that SA3443
inhibits VEGF production induced by hypoxia. Moreover, it
has been shown that high dose SA3443 treatment reduces the
leakage and the size of CNV, and suppresses the VEGF protein
levels induced by photocoagulation. Whether VEGF upregula-
tion is localized within the CNV lesion is not clariﬁed by this
study, as the sclera, choroid, retinal pigment epithelium, and
neural retina were not separated. It is, however, generally ac-
cepted that VEGF is upregulated in the CNV lesion in this
model [5]. Although it remains unknown whether the upregula-
tion of VEGF in the CNV lesion is related to hypoxia, it is likely
that the inhibitory activity of SA3443 of CNV is mediated, at
least in part, by inhibiting the upregulation of VEGF protein.
Fig. 3. SA3443 inhibits CNV growth. Eﬀects of SA3443 treatment on the lesion size as assessed using choroidal ﬂatmounts on days 3 (A) and 7 (B).
Representative photographs of the lesions are shown. Left, middle and right panels show the CNV lesion from the control, low-dose (100 mg/kg), and
high-dose (300 mg/kg) groups. The average lesion size is shown in (C). Bars show the mean lesion size; error bars indicate S.D. \: P < 0.05 and :
P < 0.01 vs. non-treated control. Bars 100 lm. Original magniﬁcation 400·.
Fig. 4. SA3443 downregulates the expression of VEGF in the laser-
treated eyes. Eﬀects of SA3443 on the expression of VEGF in the
lasered eyes on days 3 and 7 from low-dose (100 mg/kg) and high-dose
(300 mg/kg) groups were examined by ELISA analysis. Graphs show
the average; error bars indicate S.D. (n = 6 in each group). \:
Bonferroni corrected P < 0.05 vs. non-treated control.
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expression of pro-angiogenic genes in response to hypoxic con-
ditions, and plays an important role in vasculogenesis and
angiogenesis [29]. In vivo, HIF-1a is increased in ischemic ret-
ina and subsequently upregulates the expression of VEGF [30].
Furthermore, the overexpression of HIF-1a by adenovirus in
the retina induces retinal angiogenesis. However, it was found
that the expression of HIF-1a was not aﬀected by SA3443
treatment in vitro (data not shown). Thus, SA3443 is likely
to either regulate the downstream factor(s) of HIF-1a or act
independently of HIF-1a [31]. The underlying molecular mech-anism of VEGF downregulation by SA3443 is an issue for fu-
ture research.
SA3443 was shown to modulate immune reactions [8–19].
This and other studies have shown that anti-inﬂammatory com-
pounds including steroids [32], non-steroidal anti-inﬂammatory
drugs (NSAIDs) [7,33] and other immunomodulatory drugs
[5,34], suppress the CNV growth. A possible mechanism for
these anti-angiogenic actions of these compounds is the down-
regulation of the VEGF expression as demonstrated in this
and other studies [35]. Besides the eﬀects of VEGF on the
CNV activity, it is worth mentioning that the activity of CNV
is also mediated by inﬂammatory process [36]. Recent studies
suggest that immune responsesmediated bymacrophage/mono-
cyte [37–39] and complement pathways [40] play important roles
in the CNV growth. It is highly likely that, considering their
pharmacological properties, anti-inﬂammatory compounds
such as SA3443 also aﬀect leukocyte inﬁltration into the CNV
lesion. The observation that the inhibitory eﬀect of SA3443 on
the CNV growth was apparent only at day 7 but not at day 3
in vivo, may support the theory that SA3443 aﬀects immune
reactions such as leukocyte inﬁltration, thereby modulating
the angiogenesis process rather than inhibiting angiogenesis it-
self and thus suppresses CNV. To develop novel strategies for
the CNV treatment, it would be important to address whether
the modiﬁcation of the leukocyte response by such compounds
plays a central part in suppressing the CNV activity.
In summary, we have shown SA3443 suppresses the upregu-
lation of VEGF and inhibits CNV growth. Although further
studies are necessary, this compound may be eﬀective for
CNV treatment.
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